Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,659
archived clinical trials in
Metabolic

An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated:  9/25/2013
Duke Clinical Research Unit
mi
from
Durham, NC
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated: 9/25/2013
Duke Clinical Research Unit
mi
from
Durham, NC
Click here to add this to my saved trials
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated:  9/25/2013
University of Texas Health Science Center at Houston
mi
from
Houston, TX
An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia
Status: Enrolling
Updated: 9/25/2013
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Discovering New Biomarkers For Monitoring Disease Progression in Patients With Mucopolysaccharidosis IVA
Discovering New Biomarkers for Monitoring Disease Progression in Patients With Mucopolysaccharidosis IVA (MPSIVA).
Status: Enrolling
Updated:  12/17/2013
Emory University, Dept of Human Genetics
mi
from
Decatur, GA
Discovering New Biomarkers For Monitoring Disease Progression in Patients With Mucopolysaccharidosis IVA
Discovering New Biomarkers for Monitoring Disease Progression in Patients With Mucopolysaccharidosis IVA (MPSIVA).
Status: Enrolling
Updated: 12/17/2013
Emory University, Dept of Human Genetics
mi
from
Decatur, GA
Click here to add this to my saved trials
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
An Open-label, Single and Repeat Single Ascending Dose Escalation Study to Compare the Pharmacokinetics of Metformin Eicosapentaenoate With Metformin Hydrochloride and Icosapent Ethyl Following Oral Administration to Healthy Volunteers
Status: Enrolling
Updated:  4/10/2014
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
An Open-label, Single and Repeat Single Ascending Dose Escalation Study to Compare the Pharmacokinetics of Metformin Eicosapentaenoate With Metformin Hydrochloride and Icosapent Ethyl Following Oral Administration to Healthy Volunteers
Status: Enrolling
Updated: 4/10/2014
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Stem Cell Transplant w/Laronidase for Hurler
Phase II Study of Combined Laronidase (AldurazymeTM) Enzyme Replacement Therapy (ERT) With Hematopoietic Stem Cell Transplantation (HSCT) for Hurler Syndrome (MPS IH)
Status: Enrolling
Updated:  7/8/2014
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Stem Cell Transplant w/Laronidase for Hurler
Phase II Study of Combined Laronidase (AldurazymeTM) Enzyme Replacement Therapy (ERT) With Hematopoietic Stem Cell Transplantation (HSCT) for Hurler Syndrome (MPS IH)
Status: Enrolling
Updated: 7/8/2014
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Beta-carotene Absorption and Bioconversion to Vitamin A From Biofortified Cassava Gari
Beta-carotene Absorption and Bioconversion to Vitamin A in a Biofortified Cassava Gari Meal and a White Cassava Gari Meal With Added Red Palm Oil
Status: Enrolling
Updated:  8/5/2014
USDA, ARS, Western Human Nutrition Research Center
mi
from
Davis, CA
Beta-carotene Absorption and Bioconversion to Vitamin A From Biofortified Cassava Gari
Beta-carotene Absorption and Bioconversion to Vitamin A in a Biofortified Cassava Gari Meal and a White Cassava Gari Meal With Added Red Palm Oil
Status: Enrolling
Updated: 8/5/2014
USDA, ARS, Western Human Nutrition Research Center
mi
from
Davis, CA
Click here to add this to my saved trials
Study of Arm and Putter Movement in Golfers With Golfer's Cramp
Golfer&Apos;s Cramp: Correlation of Wrist Movements and Surface EMG With Putter Movements
Status: Enrolling
Updated:  8/22/2014
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Study of Arm and Putter Movement in Golfers With Golfer's Cramp
Golfer&Apos;s Cramp: Correlation of Wrist Movements and Surface EMG With Putter Movements
Status: Enrolling
Updated: 8/22/2014
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated:  4/8/2015
Clinical Research Facility
mi
from
Santa Barbara, CA
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated: 4/8/2015
Clinical Research Facility
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated:  4/8/2015
Clinical Research Facility
mi
from
Chicago, IL
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated: 4/8/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated:  4/8/2015
Clinical Research Facility
mi
from
Ann Arbor, MI
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated: 4/8/2015
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated:  4/8/2015
Local Institution
mi
from
Reno, NV
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated: 4/8/2015
Local Institution
mi
from
Reno, NV
Click here to add this to my saved trials
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated:  4/8/2015
Clinical Research Facility
mi
from
Greenville, NC
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
Status: Enrolling
Updated: 4/8/2015
Clinical Research Facility
mi
from
Greenville, NC
Click here to add this to my saved trials
HSCT for High Risk Inherited Inborn Errors
Treatment of High Risk, Inherited Lysosomal And Peroxisomal Disorders by Reduced Intensity Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  4/22/2015
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
HSCT for High Risk Inherited Inborn Errors
Treatment of High Risk, Inherited Lysosomal And Peroxisomal Disorders by Reduced Intensity Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 4/22/2015
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared With Imiglucerase in Patients With Type I Gaucher Disease
Status: Enrolling
Updated:  7/16/2015
Duke Children's Hospital and Health Center
mi
from
Durham, NC
Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared With Imiglucerase in Patients With Type I Gaucher Disease
Status: Enrolling
Updated: 7/16/2015
Duke Children's Hospital and Health Center
mi
from
Durham, NC
Click here to add this to my saved trials
Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared With Imiglucerase in Patients With Type I Gaucher Disease
Status: Enrolling
Updated:  7/16/2015
Your Health S.A.
mi
from
Buenos Aires,
Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared With Imiglucerase in Patients With Type I Gaucher Disease
Status: Enrolling
Updated: 7/16/2015
Your Health S.A.
mi
from
Buenos Aires,
Click here to add this to my saved trials
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated:  7/16/2015
St. Joseph's Hospital
mi
from
Phoenix, AZ
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated: 7/16/2015
St. Joseph's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated:  7/16/2015
Pediatric Clinical Research Center, Children's Hospital Oakland
mi
from
Oakland, CA
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated: 7/16/2015
Pediatric Clinical Research Center, Children's Hospital Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated:  7/16/2015
The Children's Hospital
mi
from
Denver, CO
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated: 7/16/2015
The Children's Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated:  7/16/2015
Harbin Clinic
mi
from
Rome, GA
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated: 7/16/2015
Harbin Clinic
mi
from
Rome, GA
Click here to add this to my saved trials
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated:  7/16/2015
Mid-Illinois Hematology & Oncology Associates, Ltd
mi
from
Normal, IL
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated: 7/16/2015
Mid-Illinois Hematology & Oncology Associates, Ltd
mi
from
Normal, IL
Click here to add this to my saved trials
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated:  7/16/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated: 7/16/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated:  7/16/2015
Children's Hospital Boston
mi
from
Boston, MA
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated: 7/16/2015
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated:  7/16/2015
Saint Louis University Cardinal Glennon Children's Hospital
mi
from
St. Louis, MO
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated: 7/16/2015
Saint Louis University Cardinal Glennon Children's Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated:  7/16/2015
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated: 7/16/2015
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated:  7/16/2015
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated: 7/16/2015
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated:  7/16/2015
Upstate Medical University, State University of New York (SUNY)
mi
from
Syracuse, NY
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated: 7/16/2015
Upstate Medical University, State University of New York (SUNY)
mi
from
Syracuse, NY
Click here to add this to my saved trials
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated:  7/16/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated: 7/16/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated:  7/16/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated: 7/16/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated:  7/16/2015
Baylor College of Medicine/Texas Children's Hospital
mi
from
Houston, TX
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated: 7/16/2015
Baylor College of Medicine/Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated:  7/16/2015
University Of Utah Hospital
mi
from
Salt Lake City, UT
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated: 7/16/2015
University Of Utah Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated:  7/16/2015
Franciscan Skemp Healthcare
mi
from
La Crosse, WI
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated: 7/16/2015
Franciscan Skemp Healthcare
mi
from
La Crosse, WI
Click here to add this to my saved trials
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated:  7/16/2015
Fundacao Universidade de Ciencias da Saude de Alagoas Governador Lamenha Filho / UNCISAL
mi
from
Maceio,
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy
Status: Enrolling
Updated: 7/16/2015
Fundacao Universidade de Ciencias da Saude de Alagoas Governador Lamenha Filho / UNCISAL
mi
from
Maceio,
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Auburn, ME
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Auburn, ME
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
Status: Enrolling
Updated:  7/27/2015
Clinical Research Facility
mi
from
Miami, FL
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia
Status: Enrolling
Updated: 7/27/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
A Randomized, Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy, and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Addison, IL
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
A Randomized, Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy, and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Addison, IL
Click here to add this to my saved trials
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
A Randomized, Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy, and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Kansas City, KA
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
A Randomized, Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy, and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
A Randomized, Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy, and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Cincinnati, OH
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
A Randomized, Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy, and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
A Randomized, Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy, and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Philadelphia, PA
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
A Randomized, Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy, and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
A Randomized, Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy, and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
Status: Enrolling
Updated:  7/29/2015
Clinical Research Facility
mi
from
Philadelphia, PA
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
A Randomized, Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy, and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
Status: Enrolling
Updated: 7/29/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
A Randomized, Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy, and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
Status: Enrolling
Updated:  7/29/2015
Research Site
mi
from
Chocoutimi,
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
A Randomized, Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy, and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
Status: Enrolling
Updated: 7/29/2015
Research Site
mi
from
Chocoutimi,
Click here to add this to my saved trials
Treatment of Muscle Cramps in Patients With Liver Cirrhosis
A Pilot Study of Hydroxychloroquine for the Treatment of Muscle Cramps in Patients With Cirrhosis
Status: Enrolling
Updated:  7/29/2015
The Mayo Clinic
mi
from
Rochester, MN
Treatment of Muscle Cramps in Patients With Liver Cirrhosis
A Pilot Study of Hydroxychloroquine for the Treatment of Muscle Cramps in Patients With Cirrhosis
Status: Enrolling
Updated: 7/29/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease
Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease
Status: Enrolling
Updated:  7/31/2015
Children's Hospitals and Clinics of Minnesota
mi
from
Minneapolis, MN
Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease
Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease
Status: Enrolling
Updated: 7/31/2015
Children's Hospitals and Clinics of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease
Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease
Status: Enrolling
Updated:  7/31/2015
Gillette Children's Specialty Healthcare
mi
from
St Paul, MN
Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease
Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease
Status: Enrolling
Updated: 7/31/2015
Gillette Children's Specialty Healthcare
mi
from
St Paul, MN
Click here to add this to my saved trials
Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome
Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome Type A and Maroteaux-Lamy Syndrome
Status: Enrolling
Updated:  8/10/2015
Greenwood Genetic Center
mi
from
Greenville, SC
Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome
Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome Type A and Maroteaux-Lamy Syndrome
Status: Enrolling
Updated: 8/10/2015
Greenwood Genetic Center
mi
from
Greenville, SC
Click here to add this to my saved trials
Effects of Enzyme Replacement in Gaucher's Disease
Clinical and Biochemical Effects of Macrophage-Targeted Glucocerebrosidase on Neurological Involvement in Neuronopathic Gaucher's Disease
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Effects of Enzyme Replacement in Gaucher's Disease
Clinical and Biochemical Effects of Macrophage-Targeted Glucocerebrosidase on Neurological Involvement in Neuronopathic Gaucher's Disease
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Analysis of the Nervous System in Patients With Fabry's Disease
The Natural History and Pathogenesis of Fabry Disease
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Analysis of the Nervous System in Patients With Fabry's Disease
The Natural History and Pathogenesis of Fabry Disease
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
The Natural History and Pathogenesis of Mucolipidosis Type IV
The Natural History and Pathogenesis of Mucolipidosis Type IV
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
The Natural History and Pathogenesis of Mucolipidosis Type IV
The Natural History and Pathogenesis of Mucolipidosis Type IV
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease
A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease
A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials